alvelestat (MPH966) / Mereo Biopharma 
Welcome,         Profile    Billing    Logout  
 15 Diseases   2 Trials   2 Trials   178 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
alvelestat (MPH966) / Mereo Biopharma
2007-004584-22: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Sputum after Challenge with Inhaled Lipopolysaccharide (LPS)

Ongoing
2
16
Europe
AZD9668 tosylate, AZD9668,
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
 
 
ATALANTa, NCT03679598: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Hourglass Jul 2021 - Dec 2021 : From ATALANTA trial for alpha-1 antitrypsin deficiency
Completed
2
63
US
Alvelestat (MPH966), Placebo
University of Alabama at Birmingham, National Institutes of Health (NIH), Mereo BioPharma, National Center for Advancing Translational Sciences (NCATS)
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
11/23
12/23
NCT02669251: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
1/2
34
US
MPH966
National Cancer Institute (NCI)
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome
12/27
12/27

Download Options